An observational, non-interventional, multi-center, chart review study conducted among patients enrolled in an AZD9291 early access program in Hong Kong, with locally advanced/metastatic EGFR T790M mutation-positive NSCLC and prior exposure to EGFR TKI therapy.
Non-small Cell Lung Cancer
18 Years - 100 Years
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: -
Verified 01 Sept 2021 by AstraZeneca
No locations available
|EGFR T790M positive NSCLC patients|
Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI treatment.